# Initial Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/initial-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.initialtx.com
- Total disclosed funding: $3.8M
- Latest round: Series A (Feb 3, 2021)
- Investors on record: 1

## About

Based in California, US, and co-founded by Jamie H.D. Cate, Spiros Liras (CEO), Brian Paegel, and Kevan Shokat in 2020, Initial Therapeutics, Inc. launched by Apple Tree Partners (ATP), operates as a biotechnology company that focuses on developing small-molecule medicine for difficult-to-drug protein targets to prevent the onset of diseases. In April 2023, the firm raised USD 75 million in series A funding led by investor Apple Tree Partners.

The company has developed an approach to disease intervention by targeting specific high-value protein targets using selective termination of protein synthesis (STOPS) in the exit tunnel of the ribosome. By leveraging this platform, STOPS, the company designs small-molecule medicines to halt pathogenic protein formation in the earliest stages.

The company plans to utilize its April 2023 funding to support the discovery of new therapeutics.

## Funding rounds

- Series A, Feb 3, 2021, $2.8M — Apple Tree Partners
- Series A, Jul 16, 2020, $1M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A